Probiotics for preventing acute otitis media in children (Protocol)

Scott AM, Beller EM, Clark J, Roos K, Grimwood K, Little P, Del Mar CB


www.cochranelibrary.com
**TABLE OF CONTENTS**

<table>
<thead>
<tr>
<th>Section</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>HEADER</td>
<td>1</td>
</tr>
<tr>
<td>ABSTRACT</td>
<td>1</td>
</tr>
<tr>
<td>BACKGROUND</td>
<td>1</td>
</tr>
<tr>
<td>OBJECTIVES</td>
<td>2</td>
</tr>
<tr>
<td>METHODS</td>
<td>2</td>
</tr>
<tr>
<td>ACKNOWLEDGEMENTS</td>
<td>5</td>
</tr>
<tr>
<td>REFERENCES</td>
<td>5</td>
</tr>
<tr>
<td>APPENDICES</td>
<td>6</td>
</tr>
<tr>
<td>CONTRIBUTIONS OF AUTHORS</td>
<td>7</td>
</tr>
<tr>
<td>DECLARATIONS OF INTEREST</td>
<td>7</td>
</tr>
<tr>
<td>SOURCES OF SUPPORT</td>
<td>8</td>
</tr>
</tbody>
</table>

Probiotics for preventing acute otitis media in children (Protocol)  
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Probiotics for preventing acute otitis media in children

Anna M Scott1, Elaine M Beller1, Justin Clark1, Kristian Roos2, Keith Grimwood3, Paul Little4, Chris B Del Mar1

1Centre for Research in Evidence-Based Practice (CREBP), Bond University, Gold Coast, Australia. 2ENT Department, Lundby Hospital, Goteborg, Sweden. 3School of Medicine and Menzies Health Institute Queensland, Griffith University and Departments of Infectious Diseases and Paediatrics, Gold Coast Health, Gold Coast, Australia. 4Primary Care and Population Sciences, Faculty of Medicine, Alder Moor Health Centre, University of Southampton, Southampton, UK

Contact address: Anna M Scott, Centre for Research in Evidence-Based Practice (CREBP), Bond University, 14 University Drive, Gold Coast, Queensland, 4229, Australia. ascott@bond.edu.au.

Editorial group: Cochrane Acute Respiratory Infections Group.


Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

ABSTRACT

This is a protocol for a Cochrane Review (Intervention). The objectives are as follows:

To assess the effects of probiotics to prevent the occurrence and reduce the severity of acute otitis media in children.

BACKGROUND

Description of the condition

Acute otitis media (AOM) is one of the most common childhood diseases. It is characterised by effusion of the middle ear and rapid onset of symptoms such as ear pain, otorrhoea (discharge from the ear), fever, and malaise (AAP 2013). Although AOM has low mortality, it has high morbidity (Stool 1989); by two years of age, 70% of children have had at least one episode of AOM, and 20% to 30% of children have experienced three or more episodes (Hatakka 2007). Globally, the incidence rate of AOM is estimated at 10.85% (the equivalent of 709 million cases of AOM each year); the incidence rate varies, from a low of 3.64% in Central Europe to 43.37% in central sub-Saharan Africa (Monasta 2012).

Clinical care guidelines for treatment of AOM vary internationally. For mild-moderate cases, ‘watchful waiting’ has now been adopted in many high-income countries, although this remains infrequent in low-income countries (Tamir 2017). Most guidelines recommend amoxicillin as first-line treatment, with some exceptions: amoxicillin-clavulanate in some high-income countries, penicillin V in Scandinavian countries, and other first-line treatments in low-income countries include trimethoprim-sulfamethoxazole, cephalaxin, cloxacillin, and others (Tamir 2017). Although AOM is one of the main reasons for antibiotic prescription in children (Hendley 2002), the rates of antibiotic prescription for AOM vary internationally, from 56% of consultations for AOM in the Netherlands, Akkerman 2005, to 95% in North America (Froom 2001). However, using antibiotics in prophylaxis and treatment of AOM leads to the development of antibiotic resistance, and identification of alternatives to antibiotics for prevention or treatment of AOM is becoming urgent (Cohen 2013; Hatakka 2007; Niittynen 2012).

Description of the intervention

The World Health Organization (WHO) defines probiotics as live micro-organisms that confer a health benefit on the host when...
administered in adequate amounts (FAO-WHO 2006). Microorganisms used as probiotics include: Lactobacillus (e.g. L acidophilus, L fermentum), Bifidobacterium (e.g. B bifidum, B lactis), Streptococcus (e.g. S thermophilus) species, and Saccharomyces (e.g. S boulardii) species (Niittynen 2012). Probiotics are available in multiple forms: as tablets or powders (regulated as dietary supplements), as a food ingredient (e.g. yogurts or kefirs) (Wang 2016), or directly applied by spray to the throat (Roos 2001). Probiotics are not currently part of clinical practice. Probiotics can be used by adults and children (Wang 2016). In people with unimpaired immune systems, probiotics do not have any known harmful effects (Marteau 2002).

How the intervention might work
Since otitis media is associated with colonisation by pathogenic bacteria in the nasopharynx, and disruption of the balance of the normal microbiota (Hatakka 2007), probiotics may act by restoring the normal microbiota (i.e. by overwhelming the pathogens with healthy commensals), rather than by attempting to kill pathogens with antibiotics, although the mechanisms of any probiotics benefit are unclear (Hao 2015). They may act by stabilising gut microbiota; modulating immune function; competing with pathogens for essential nutrients and adhesion sites on epithelial surfaces; producing bacteriocins or other inhibitory substances (Hao 2015; Hatakka 2007; Niittynen 2012).

Why it is important to do this review
Because antibiotic use leads to increased antibiotic resistance, (O’Neill 2014), other options (including probiotics) are attracting greater interest (Hatakka 2007). The most recent Cochrane Review on the use of probiotics for preventing acute respiratory tract infections did not include studies with AOM as an outcome on the grounds that otitis-prone children may have immunodeficiencies (Hao 2015). Several other Cochrane Reviews have investigated other interventions for the prevention of otitis media. These include xylitol (Azarpazhooh 2016), pneumococcal conjugate vaccines (Fortanier 2014), influenza vaccines (Norhayati 2015), and antibiotics (Leach 2013).

O B J E C T I V E S
To assess the effects of probiotics to prevent the occurrence and reduce the severity of acute otitis media in children.

M E T H O D S

Criteria for considering studies for this review

Types of studies
We will include randomised controlled trials (RCTs), irrespective of type (e.g. cluster, parallel, cross-over). We will include studies reported as full text, those published as abstracts only, and unpublished data.

Types of participants
We will include children (aged up to 18 years) diagnosed with acute otitis media (AOM) by a clinician. We will exclude children with the following comorbidities or characteristics: chromosomal and genetic disorders; craniofacial abnormalities, including cleft palate; those taking systemic corticosteroids or with immune deficiency status; and those with cystic fibrosis or primary ciliary dyskinesia.

Types of interventions
We will include trials comparing probiotics (including: Lactobacillus spp, Bifidobacterium spp, Streptococcus spp, and Saccharomyces spp) with placebo or usual care or lack of treatment. We will include probiotics of any composition (e.g. powder, drink, spray). We will include studies that include a co-intervention (including antibiotics) that is applied to both the intervention and control groups, and we will perform a subgroup analysis for those studies.

Types of outcome measures

Primary outcomes
1. Incidence of AOM.
2. Severity of AOM.
3. Adverse events (e.g. gastrointestinal side effects).

Secondary outcomes
1. Median duration of AOM episodes (days).
2. Difference between probiotic and non-probiotic groups in use of antibiotics to treat AOM (e.g. dose, duration)
3. Time off school (for the child) (e.g. in days or hours)
4. Time off work (for the parent or carer) (e.g. in days or hours)
5. Difference between probiotic and non-probiotic groups in hearing loss, if AOM occurs.
7. Reduction in referrals to a specialist (e.g. for glue ear).
8. Reduction in other infections (respiratory and gastrointestinal).
9. Compliance with taking probiotics (e.g. measured by pill count or weight of the spray bottle).
10. Quality of life measures (using any validated quality of life measure).
11. Difference in use of other treatments (e.g. differences in dosage of analgesics, decongestants).

**Search methods for identification of studies**

**Electronic searches**

We will search the following databases from inception to present.
- Cochrane Acute Respiratory Infections Group Specialized Register
- CENTRAL (Cochrane Central Register of Controlled Trials)
- MEDLINE (PubMed)
- Embase
- CINAHL (Cumulative Index to Nursing and Allied Health Literature)
- Web of Science
- LILACS (Latin American and Caribbean Health Sciences Literature database)

We will use the search strategy described in Appendix 1 to search PubMed. We will combine the PubMed search with the Cochrane Highly Sensitive Search Strategy for randomised trials: sensitivity and precision-maximising version (2008 revision) (Lefebvre 2011). We will not impose any language, publication date, or publication status restrictions. We will convert the search for use in the other databases.

We will also conduct a search of ClinicalTrials.gov (www.clinicaltrials.gov) and the WHO International Clinical Trials Registry Platform (apps.who.int/trialsearch/) to identify published registered trials, as well as ongoing studies. Where relevant, for completed trials that appear to be unpublished, we will contact trial investigators for unpublished data.

We will run backward (cited) and forward (citing) citation analyses for all included studies. We will also use the similar article feature in PubMed and the shared citation matcher in Web of Science to identify any potential trials missed by the search strategy.

**Searching other resources**

We will contact experts in the field to identify additional unpublished materials.

**Data collection and analysis**

**Selection of studies**

Two review authors (AMS, JC) will independently screen titles and abstracts for inclusion of all the potential studies we identify as a result of the search.

We will retrieve the full-text study reports/publication, and two review authors (AMS, JC) will independently screen the full text and identify studies for inclusion, and identify and record reasons for exclusion of the ineligible studies. Any disagreements will be resolved through discussion or by consulting a third review author (CDM) when necessary. We will identify and exclude duplicates and collate multiple reports of the same study so that each study rather than each report is the unit of interest in the review. We will record the selection process in sufficient detail to complete a PRISMA flow diagram and ‘Characteristics of excluded studies’ table (Moher 2009). We will not impose any language restrictions.

**Data extraction and management**

We will use a data collection form for study characteristics and outcome data that has been piloted on at least one study in the review. Two review authors (AMS, JC) will extract the following study characteristics from included studies.

1. Methods: study location, study design, study objective, study duration
2. Participants: N, type of participants, mean age, age range, gender, comorbidities, number of previous episodes of otitis media, diagnostic criteria
3. Interventions: probiotic type, duration, dose, comparison, other permitted interventions (e.g. concomitant analgesics, decongestants), other prohibited interventions (e.g. analgesics, decongestants)
4. Outcomes: primary and secondary outcomes specified and collected, and time points reported
5. Notes: funding for trial, and notable conflicts of interest of trial authors

Two review authors (AMS, JC) will independently extract outcome data from the included studies. We will note in the ‘Characteristics of included studies’ table if outcome data are not reported in a usable way. Any disagreements will be resolved by consensus or by involving a third review author (CDM). One review author (EB) will transfer data into the Review Manager 5 file (RevMan 2014). We will double-check that data are entered correctly by comparing the data presented in the systematic review with the study reports. A second review author (CDM) will spot-check study characteristics for accuracy against the trial report.

**Assessment of risk of bias in included studies**

Two review authors (AMS, JC) will independently assess risk of bias for each study using the criteria outlined in the Cochrane Handbook for Systematic Reviews of Interventions (Higgins 2011). Any disagreements will be resolved by discussion or by involving
another review author (EB, CDM). We will assess the risk of bias according to the following domains.
1. Random sequence generation
2. Allocation concealment
3. Blinding of participants and personnel
4. Blinding of outcome assessment
5. Incomplete outcome data
6. Selective outcome reporting
7. Other bias
We will grade each potential source of bias as high, low, or unclear and provide a quote from the study report together with a justification for our judgement in the 'Risk of bias' table. We will summarise the 'Risk of bias' judgements across different studies for each of the domains listed. Where necessary, we will consider blinding separately for different key outcomes. Where information on risk of bias relates to unpublished data or correspondence with a trialist, we will note this in the 'Risk of bias' table. When considering treatment effects, we will take into account the risk of bias for the studies that contribute to that outcome.

Assessment of bias in conducting the systematic review
We will conduct the review according to this published protocol and report any deviations from it in the 'Differences between protocol and review' section of the systematic review.

Measures of treatment effect
We will enter the outcome data for each study into the data tables in Review Manager 5 to calculate the treatment effects (RevMan 2014). We will use risk ratios for dichotomous outcomes, rate ratios for outcomes measured as rates (e.g. adverse events), and mean differences or standardised mean differences for continuous outcomes. We will undertake meta-analyses only where this is meaningful, that is if the treatments, participants, and the underlying clinical question are similar enough for pooling to make sense. If meta-analysis is possible, we will use a random-effects model for high heterogeneity and a fixed-effect model for low heterogeneity.

Unit of analysis issues
We will use the participant as the unit of analysis, except for any cluster RCTs.

Dealing with missing data
We will contact investigators or study sponsors to verify key study characteristics and obtain missing numerical outcome data where possible (e.g. when a study is identified as abstract only). Where this is not possible, and the missing data are thought to introduce serious bias, we will explore the impact of including such studies in the overall assessment of results by a sensitivity analysis. If numerical outcome data such as standard deviations or correlation coefficients are missing, and they cannot be obtained from the authors, we will calculate them from other available statistics such as P values according to the methods described in the Cochrane Handbook for Systematic Reviews of Interventions (Higgins 2011).

Assessment of heterogeneity
We will use the I² statistic to measure heterogeneity among the trials in each analysis. If we identify substantial heterogeneity, we will report it and explore possible causes by prespecified subgroup analysis. We will consider an I² statistic value of 0% to 40% to be low heterogeneity, 41% to 60% as moderate heterogeneity, 61% to 90% substantial heterogeneity, and over 91% to be considerable heterogeneity (Higgins 2011).

Assessment of reporting biases
If we are able to pool more than 10 trials, we will create and examine a funnel plot to explore possible small-study and publication biases.

Data synthesis
We will pool data from studies we judge to be clinically homogeneous using Review Manager 5 software (RevMan 2014). If more than one study provides usable data in any single comparison, we will perform a meta-analysis. As sizeable heterogeneity is expected in terms of populations, probiotics studied, etc., we will use the random-effects model. If an insufficient volume of evidence exists to perform a meta-analysis, we will report outcomes in a narrative format.

GRADE and ‘Summary of findings’ table
We will create a ‘Summary of findings’ table using the following outcomes: incidence of AOM, severity of AOM, adverse events, median duration of AOM episodes, difference between groups in antibiotic use, time off school (child), time off work (parent or carer). We will use the five GRADE considerations (study limitations, consistency of effect, imprecision, indirectness, and publication bias) to assess the quality of a body of evidence as it relates to the studies that contribute data to the meta-analyses for the prespecified outcomes (Atkins 2004). We will use methods and recommendations described in Section 8.5 and Chapter 12 of the Cochrane Handbook for Systematic Reviews of Interventions (Higgins 2011), employing GRADEpro GDT software (GRADEpro GDT 2014). We will justify all decisions to down- or upgrade the quality of studies using footnotes, and we will make comments to aid the reader’s understanding of the review where necessary.
Subgroup analysis and investigation of heterogeneity

We plan to carry out the following subgroup analyses.
1. Child’s age (≤ two years: see Rovers 2006)
2. Type of probiotic
3. Children with severe AOM (fever > 39 °C; bilateral otitis; or perforation of the tympanic membrane, see Rovers 2006)
4. Studies that include a co-intervention (including antibiotics) that is applied to both the intervention and control groups

We will use the Chi² test to test for subgroup interactions in Review Manager 5 (RevMan 2014).

Sensitivity analysis

We plan to carry out the following sensitivity analysis.
1. Including versus excluding studies with two or more domains rated as at high risk of bias

ACKNOWLEDGEMENTS

The authors would like to acknowledge and thank the authors of Crosby 2004, whose withdrawn protocol partly informed development of this protocol. Parts of the Background are based on a Cochrane Review by Venekamp 2015. One of the present authors (CDM) is also an author of Crosby 2004 and Venekamp 2015. The Methods section of this protocol is based on a standard template developed by the Cochrane Airways Group and adapted by the Cochrane Acute Respiratory Infections Group. We wish to thank the following people for commenting on the draft of this protocol: Catherine Marshall, Jenny Negus, Roderick Venekamp, Tal Marom, Robert Ware, and Zulfiqar Bhutta.

REFERENCES

AAP 2013

Akkerman 2005

Atkins 2004

Azarpazhooh 2016

Cohen 2013

FAO-WHO 2006

Hendley 2002

Fortanier 2014

Froom 2001

GRADepro GDT 2014
[Computer program]
GRADE Working Group, McMaster University. GRADepro GDT. Hamilton (ON): GRADE Working Group, McMaster University, 2014.

Hao 2015

Hatakka 2007

Hendley 2000

Additional references
Higgins 2011

Leach 2013

Lefebvre 2011

Marteau 2002

Moher 2009

Monasta 2012

Niittynen 2012

Norhayati 2015

O’Neill 2014

RevMan 2014 [Computer program]

Rovers 2006

Stool 1989

Tamir 2017

Venekamp 2015

Wang 2016

References to other published versions of this review

Crosby 2004

* Indicates the major publication for the study
APPENDICES

Appendix 1. PubMed (National Library of Medicine) search strategy


AND


AND


NOT (Animals[Mesh] not (Animals[Mesh] and Humans[Mesh])))

CONTRIBUTIONS OF AUTHORS

Draft the protocol: AMS, KG, EB, KR, JC, PL, CDM

Develop the search strategy: JC

Run the search strategy: JC

Obtain copies of studies: JC

Select which studies to include: AMS, JC

Extract data from studies: AMS, JC

Enter data into Review Manager 5: AMS, JC, EB

Carry out the analysis: EB

Interpret the analysis: AMS, KG, EB, KR, JC, PL, CDM

Draft the final review: AMS, KG, EB, KR, JC, PL, CDM

Check correct use of grammar: CDM

Update the review: AMS, CDM
DECLARATIONS OF INTEREST

Anna M Scott: Salary funded by the Centre for Research Excellence in Minimising Antibiotic Resistance from Acute Respiratory Infections (CREMARA), which itself is funded by the National Health and Medical Research Council (NHMRC), Australia.

Elaine Beller: This review was supported in part by research grants from the NHMRC, Australia, to the Centre for Evidence-Based Practice, Bond University.

Justin Clark: Salary funded by the Centre for Research Excellence in Minimising Antibiotic Resistance from Acute Respiratory Infections (CREMARA), which itself is funded by the National Health and Medical Research Council (NHMRC), Australia.

Kristian Roos: I am a minor shareholder of a small biomedical company (ESSUM AB). This company has been doing research for many years with probiotic bacteria. ESSUM AB has no patent in probiotic bacteria that might be used for acute otitis media, and ESSUM has no intention of doing research into acute otitis media.

Keith Grimwood: None known.

Paul Little: A study PL was Chief Investigator for, had placebo and probiotic tablets provided by a commercial company that makes probiotic (Cultech).

Chris Del Mar: reports CREMARA institutional funding (NHMRC); Cochrane Acute Respiratory Infections Group institutional funding (NHMRC); institutional and personal funding from the Australian Commission on Safety and Quality in Health Care for the development of patient decision aids; personal consulting funding for shared decision-making implementation (BUPA, UK); American College of Physicians (ACP) Journal Club editorial work; consultancy/providing advice to a pharmaceutical company about a proposed vaccine that might be effective against otitis media in children.

SOURCES OF SUPPORT

Internal sources

• There are no internal sources of support to report., Other.

External sources

• There are no external sources of support to report., Other.